康希諾生物(06185.HK)重組新冠病毒疫苗獲批用於序貫加強免疫接種
康希諾生物(06185.HK)公布,旗下重組新冠病毒疫苗「克威莎」獲批用於序貫加強免疫接種,完成全程接種滅活疫苗滿6個月18歲以上的目標人群,可選擇其腺病毒載體疫苗來進行序貫加強免疫接種。
國家衛健委表示,凡全程接種國藥、科興公司滅活疫苗或康希諾生物腺病毒載體疫苗滿六個月的18歲以上的目標人群,可進行一劑次同源加強免疫,也可選擇智飛生物(300122.SZ)旗下智飛龍科馬的重組蛋白疫苗,或康希諾腺病毒載體疫苗進行序貫加強免疫。對於目標人群來說,同源加強免疫接種和序貫加強免疫選擇一種即可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.